GINKGO BIOWORKS HOLDINGS, INC. financials

DNA CIK 0001830214

Source: EDGAR filings · Built 2026-06-02T02:50:38Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -179.08M -383.02M -337.60M -305.71M -311.46M -193.65M
EBITDA -256.29M -496.74M -793.90M -2.17B -1.80B -123.16M
Working Capital 375.87M 495.48M 837.89M 1.28B 1.59B 353.32M
Net Debt 272.68M -93.81M -701.82M -871.70M -1.53B -363.98M
Operating Margin -185.29% -246.54% -343.76% -462.41% -582.62% -178.75%
Net Margin -183.81% -240.94% -355.08% -440.63% -583.12% -165.16%
Return on Equity (ROE) -61.50% -76.39% -81.38% -121.23% -121.57% -27.44%
Return on Assets (ROA) -27.93% -39.71% -53.61% -82.89% -88.37% -18.75%
Current Ratio 4.92× 5.62× 6.11× 8.38× 12.79× 5.83×
Debt-to-Equity 0.86× 0.65× 0.22× 0.26× 0.01× 0.04×
Effective Tax Rate 0.27% 0.09% 0.01% 0.71% 0.08% -1.51%
Cash Conversion Ratio 0.55× 0.58× 0.33× 0.12× 0.14× 1.07×
Accruals Ratio -0.13× -0.17× -0.36× -0.73× -0.76× 0.01×
SBC % of Revenue 47.92% 49.48% 91.42% 404.15% 511.74% 0.62%
CapEx Coverage -21.33× -5.04× -7.02× -4.71× -4.40× -2.35×
Free Cash Flow Per Share $-3.23 $-7.38 $-6.94 $-7.28 $-0.23 $-0.15

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/S 2.84× 2.35× 0.34× 6.69× 42.67×
P/B 0.95× 0.75× 0.08× 1.84× 8.90×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 170.16M 227.04M 251.46M 477.71M 313.84M 76.66M
Research and Development Expense 243.77M 424.06M 580.62M 1.05B 1.15B 159.77M
Operating Expenses 485.43M 786.80M 1.12B 2.69B 2.14B 213.68M
Operating Income (Loss) -315.28M -559.76M -864.41M -2.21B -1.83B -137.03M
Income Tax Expense (Benefit) -837.00K -479.00K -71.00K -15.03M -1.48M 1.89M
Net Income (Loss) Attributable to Parent -312.76M -547.03M -892.87M -2.10B -1.83B -126.61M
Earnings Per Share, Basic $-5.64 $-10.54 $-18.37 $-50.15 $-1.35 $-0.10
Weighted Average Number of Shares Outstanding, Basic 55.46M 51.89M 48.61M 41.98M 1.36B 1.27B
Earnings Per Share, Diluted $-5.64 $-10.54 $-18.37 $-50.20 $-1.39 $-0.10
Weighted Average Number of Shares Outstanding, Diluted 55.46M 51.89M 48.61M 42.00M 1.36B 1.27B

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 167.20M 561.57M 944.07M 1.32B 1.55B 380.80M
Assets, Current 471.84M 602.74M 1.00B 1.45B 1.72B 426.54M
Assets 1.12B 1.38B 1.67B 2.54B 2.07B 675.15M
Liabilities, Current 95.97M 107.27M 163.86M 172.96M 134.76M 73.22M
Liabilities 611.11M 661.39M 568.19M 803.04M 503.61M 205.10M
Stockholders' Equity Attributable to Parent 508.59M 716.06M 1.10B 1.74B 1.51B 461.38M
Common Stock, Shares, Outstanding 58.21M 54.37M 50.03M 1.89B 1.61B 1.29B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -171.06M -319.58M -295.50M -252.20M -253.82M -135.83M
Payments to Acquire Property, Plant, and Equipment 7.67M 62.54M 40.80M 52.27M 56.52M 57.82M
Net Cash Provided by (Used in) Investing Activities -240.29M -62.24M -80.69M -67.39M -73.26M -67.12M
Net Cash Provided by (Used in) Financing Activities 17.77M -1.74M -3.22M 95.34M 1.53B 90.32M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (DNA CIK 0001830214), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

MED

Medifast, Inc.

TSSI

TSS, INC.

CRWV

CoreWeave, Inc.